Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of innovative immunotherapies for cancer and other serious diseases. Founded as a spin-off from Emergent BioSolutions in 2010 and based in Seattle, Washington, Aptevo leverages two proprietary protein-engineering platforms—ADAPTIR and TriTAC—to create next-generation modular therapeutic proteins. The ADAPTIR platform enables the rational design of bispecific and multispecific molecules tailored to engage immune cells and disease targets, while the TriTAC platform extends this approach by recruiting and activating T cells to attack tumor cells with high specificity.
Aptevo’s pipeline includes multiple product candidates designed to address both solid tumors and hematologic malignancies. Among these, lead programs target well-validated cancer antigens such as programmed cell death protein 1 (PD-1), CD20 and B-cell maturation antigen (BCMA). Each molecule is engineered to optimize pharmacokinetics, minimize off-target effects and enhance immune activation. In addition to oncology, the company is exploring applications in autoimmune and inflammatory disorders by leveraging its platform’s flexibility to fine-tune immune responses.
The company conducts global clinical trials across North America, Europe and Asia in collaboration with academic institutions and strategic partners. Aptevo maintains manufacturing and research facilities in the Seattle region, supported by contract development and manufacturing organizations (CDMOs) to ensure scalable production of its complex biologics. Regulatory interactions and clinical data reviews have positioned several candidates for potential partnerships and out-licensing discussions, reflecting Aptevo’s strategy of combining internal development with external collaboration to advance its programs efficiently.
Leadership at Aptevo is headed by President and Chief Executive Officer David Hallal, Ph.D., a biotech industry veteran with extensive experience in antibody engineering and clinical development. The executive team includes seasoned professionals in regulatory affairs, translational medicine and commercial planning. Guided by a board of directors comprising experts in oncology, immunology and corporate governance, Aptevo aims to translate its proprietary platforms into transformative therapies that address unmet medical needs and improve patient outcomes worldwide.
AI Generated. May Contain Errors.
